InvestorsHub Logo
Followers 1007
Posts 43379
Boards Moderated 0
Alias Born 03/17/2014

Re: JsTrades post# 52

Tuesday, 12/13/2022 11:27:52 AM

Tuesday, December 13, 2022 11:27:52 AM

Post# of 125
$AMAM:

this is too cheap given these results:

market is massive:


The preliminary results showed a 51.7% overall response rate (ORR) and 100% disease control rate (DCR) following treatment with ARX788. Additionally, no drug-related serious adverse events (SAEs) were noted by any patients.

With investors reacting the way they did, it’s safe to say they were impressed with the results; considering how big the breast cancer market is, the drug’s potential has caused a bit of a stir.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMAM News